Treatment of uncomplicated gonorrhea in men with single-dose moxalactam.
Men with uncomplicated urethral or rectal infection due to beta-lactamase-negative Neisseria gonorrhoeae were treated with single doses of moxalactam (1.0 g given intramuscularly). Urethral or anorectal infection was eradicated in 95 of 100 men who returned for follow-up visits three to eight days after treatment; four of eight pharyngeal gonococcal infections were eradicated. The geometric mean minimal inhibitory concentration of moxalactam for 119 pretreatment gonococcal isolates was 0.088 micrograms/ml (range, 0.008-1.0 microgram/ml), and gonococci isolated from homosexual men were significantly more resistant to moxalactam and penicillin G than were isolates from heterosexual men. Post-gonococcal urethritis (PGU) developed in 24 (29%) of 84 subjects who were followed for 12-30 days; 17 (71%) of the cases of PGU were due to Chlamydia trachomatis. Among 21 homosexual men with rectal gonorrhea, five (24%) had coexisting rectal infection with C. trachomatis. Moxalactam is comparable to other single-dose regimens for the treatment of uncomplicated urethral or anorectal gonorrhea in men due to beta-lactamase-negative N. gonorrhoeae.
D000293:Adolescent; D002692:Chlamydia trachomatis / Q000302:isolation & purification; D006069:Gonorrhea / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009070:Moxalactam / Q000627:therapeutic use*; D009344:Neisseria gonorrhoeae / Q000302:isolation & purification; D044469:Racial Groups
D009070:Moxalactam